Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for LB Pharmaceuticals Inc (LBRX : NSDQ)

• Company Description    LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression and other neuropsychiatric diseases. LB Pharmaceuticals is based in NEW YORK. Number of Employees: 27

• Price / Volume Information    Yesterday's Closing Price: $47.67 Daily Weekly Monthly 20 Day Moving Average: 270,062 shares Shares Outstanding: 32.26 (millions) Market Capitalization: $1,537.80 (millions) Beta: 52 Week High: $50.16 52 Week Low: $13.36 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.05% 6.59% 12 Week 58.64% 54.14% Year To Date 114.15% 91.97%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL One Pennsylvania Plaza Suite 1025 - New York,NY 10119 USA ph: 212-605-0300 fax: - ir@lbpharma.us https://lbpharma.us

• General Corporate Information    Officers Heather Turner - Chief Executive Officer and Director Scott Garland - Chairman of the Board and Director Marc Panoff - Senior Vice President of Finance Rekha Hemrajani - Director William Kane - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 50180M108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 32.26 Most Recent Split Date: (:1) Beta: Market Capitalization: $1,537.80 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.44 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.11 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -155.22% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -25.92 03/31/26 - -15.73 12/31/25 - -16.49 ROA 06/30/26 - -24.68 03/31/26 - -15.17 12/31/25 - -15.91 Current Ratio 06/30/26 - 15.08 03/31/26 - 35.67 12/31/25 - 41.44 Quick Ratio 06/30/26 - 15.08 03/31/26 - 35.68 12/31/25 - 41.44 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 11.59 03/31/26 - 13.21 12/31/25 - 11.91 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©